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ABSTRACT 
It has been observed that lung cancer either non-small cell or small cell is responsible for eye metastases. This form of 
metastases in several cases was the first manifestation of the disease and further investigation led to the diagnosis of the 
underlying malignancy. Both types of lung cancer are equally responsible for this demonstration. Furthermore; both 
chemotherapy and tyrosine kinase inhibitors have shown equal positive results in treating the exophalmos 
manifestation. Up to date information will be presented in our current work. 
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INTRODUCTION 
The metastatic carcinoma to the eye was considered a 
rare occurrence. Perls reported the first case of choroidal 
metastasis in 1872 (1). Malignant tumors from other 
parts of the body may spread to the eye and in the eye. 
The majorities of  intraocular metastatic tumors involve 
the choroid, but  such lesions also invade the ciliary body, 
the iris, the neural retina, the optic nerve, and in some 
cases the vitreous. Eighty percent of patients present 
with a single tumor in only one eye and 20% have 
multiple tumors, bilateral tumors, or both. Breast and 
lung cancers represent more than two-thirds of the 
primary cancer sites (2). In women, cancer metastases 
that appear in and around the eye usually arise from a 
breast cancer, and in men from lung cancer. Less 
common sites of origin may include the prostate, the 
thyroid, the gastrointestinal tract and the kidney. 
Lymphomas sometimes also invade eye or adjacent 
structures. Treatment of these tumors is efficient in 
terms of both local tumor control and preservation of 
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vision. However, metastatic lesion to the eye is a poor 
prognostic sign for the long-term survival. 
EPIDEMIOLOGY AND PATHOGENESIS 
The most common intraocular malignant neoplasm is the 
metastatic carcinoma to the eye. Statistics for the US 
indicate that 20–25% of all deaths are assignable to the 
cancer (3).   Moreover,  at the time of death, 1–2.5% of 
all people have metastatic carcinoma in at least one eye 
(4). Of these patients, about 10% have one or more 
metastatic intraocular lesions before death. 
Nevertheless, approximately 25% of individuals who are 
diagnosed with metastatic carcinoma of the eye develop 
that condition as the initial manifestation of their cancer 
(5). 
OCULAR MANIFESTATIONS 
The principal indication of metastatic carcinoma is 
blurred or distorted vision in one or both eyes. Usually, 
the pain is not a sign of metastatic cancer to the eye, 
except cases that patients have an extensive intraocular 
tumor. The characteristic metastatic carcinoma to the 
choroid from lung shows as a golden yellow to yellowish-
white round to oval lesion (6). Metastatic carcinoma to 
the optic disk may appear as a swollen disk without a 
distinct mass or as a discohesive cellular infiltration of 
the superficial aspects of the optic disk (7). Metastatic 
carcinoma to the iris shows as a solid and amelanotic 
mass (8). Ciliary body metastatic carcinoma appears as 
diffuse or as multinodular mass, often associated with 
extensive retinal detachment and severe ocular pain, 
occurring sporadically. The precise mechanism for the 
pain in this sort of ocular metastatic carcinoma is not 
clear (8). Other metastatic carcinomas to the eye include 
infiltrative lesions of the neural retina (8) and dispersed 
cells in the vitreous (9). An ophthalmologist who is 
consulted because of the visual symptoms often 
diagnoses metastatic carcinomas to the intraocular 
tissues (Fig. 1). 
DIAGNOSIS 
Imaging plays a pivotal role in the diagnosis and 
treatment of metastatic lesions. Slit-lamp photography is 
used to document anterior segment tumors. Fundus 
photography with angiography can detect small or 
hidden multifocal tumors. Orbital tumors are assessed 
using CT and/or MRI. Total body PET/CT imaging can be 
used for systemic staging or to scan occult primary 
cancers. 
Fine-needle aspiration biopsy is a reliable and safe 
technique for diagnosis in some patients (10, 11). 
 
MANAGEMENT 
The management of patients with metastasis to the eye 
involves cooperation between the eye cancer specialist, 
medical oncologist, and the radiation therapist. 
The available options for the therapy of ocular metastasis 
are observation, chemotherapy, photocoagulation, 
cryosurgery, surgical resection, or radiotherapy. The 
chosen therapy depends on the clinical condition of the 
patient. Patient with asymptomatic metastasis close to 
death probably does not need a therapy. However, a 
symptomatic patient with controlled systemic disease 
may be treated to prevent further deterioration in vision 
(12). 
 
RADIATION THERAPY 
Because lung cancer is radiation sensitive, most patients 
with uveal metastasis may be treated with relatively low-
doses of external beam radiation therapy. In some cases, 
higher doses of ophthalmic plaque irradiation or 
enucleation for radiation resistant tumors are required 
(13). 
Radiation incapacitates cells by slicing their DNA. Even 
more, it destroys blood vessels within and around the 
tumor. The radiation creates free radicals that combine 
and destroy cell components, but can affect the normal 
tissues. Modern radiation is performed either by 
inserting radioactive elements what is called 
brachytherapy. Another method is external beam 
radiation therapy (EBRT). In this case, the radiation is 
delivered from the outside of the patient and travels 
through normal tissues to the tumor. Examples of EBRT 
are linear accelerator (LINAC), gamma knife, electron 
beam and proton therapy. There are many publications 
in which the ability of EBRT to treat ocular metastasis 
successfully and effectively is documented (14–28). 
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Figure 1. Α) Exophthalmos of the Right Eye, and Β) MRI (Black Arrow 
Indicates the Lesion). 
 
Due to the current improvements in long-term survival of 
these patients, the incidence of secondary radiation 
retinopathy and local tumor recurrence has increased. 
Therefore, a need to decrease the radiation dose exists in 
order to avoid radiation oculopathy and, on the other 
hand, late tumor recurrence. The eye and orbit include 
many normal tissues with varying radiation tolerances. It 
is possible to lose the eyelashes at least temporarily with 
low doses or permanently with high-dose radiation 
therapy. The lacrimal apparatus can tolerate only low-
doses, as well. The cornea and scleral eye wall are 
resistant but the lens is very sensitive to radiation. 
 
CHEMOTHERAPY 
Systemic chemotherapy is effective in treating ocular 
metastases, especially in chemosensitive tumors such as 
smal-cell lung cancer. There are many case reports that 
have shown that chemotherapy is efficient for choroid 
metastases from non-small-cell lung cancer (29-33). 
By a systematic review of the English-language literature, 
in , of the previously reported patients with choroidal 
metastasis (most common intraocular malignancy), we 
found that the majority of patients were male (68%) and 
were ex- or current smokers (82.3%). The mean age was 
54.2 years. The most common histologic type was 
adenocarcinoma (n = 26), followed by squamous cell 
carcinoma (n = 12) and small-cell carcinoma (n = 10). The 
most frequent location of metastatic lesion was the left 
eye (n = 35), than the right eye (n = 21) or to both eyes (n 
= 5). Among the patients for whom the location of the 
primary lesion was specified, the left upper lobe (n = 16) 
was the most common site. The most common 
diagnostic modalities were bronchoscopy followed by 
the lung biopsy (n = 17) and enucleation (n = 15). Liver 
was the most common extraocular metastatic site 
identified (35%). Systemic chemotherapy was 
administrated in 60% of the patients, and the most 
common outcome was disease progression. Other ocular 
treatment modalities included radiation (n = 26), 
enucleation (n = 16), and systemic steroids (n = 9). 
Most metastatic carcinomas of the eye are progressive if 
untreated. Choroidal tumors give rise to bullous retinal 
detachment, and they can cause anterior shift of the lens 
and iris. This situation leads to secondary angle-closure 
glaucoma. Optic disk metastases produce rapid and 
thorough visual loss. Iris metastases often cause 
secondary open-angle glaucoma when the trabecular 
meshwork becomes clogged with tumor cells. If the 
patients have prolonged survival, most of them, are 
driven to a blind and painful condition. 
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CONCLUSIONS 
Metastatic tumors are the most common intraocular 
malignancies, usually located in the choroid.. The most 
frequent origins of choroidal metastasis in decreasing 
order in women are the breast, the lung, the unknown 
site, the gastrointestinal tract, the skin melanoma. In 
males the list is headed by the lung, followedthe 
unknown location, the gastrointestinal tract, the 
prostate, the kidney and the skin melanoma in men. 
The treatment options that are available are the EBRT 
and the plaque radiotherapy, the surgical resection, the 
transpupillary thermotherapy and the intravitreal 
chemotherapy. The use of chemotherapy alone for 
ocular metastases is not widely reported. All three 
options of therapy promise. For lung cancer patients with 
metastatic carcinoma into the eye, there is no a danger 
to the survival, because the eye is not a vital structure. 
The prognosis for a patient depends on the response of 
the lung carcinoma to radiotherapy and/or to the 
chemotherapy. 
Intraocular metastases are significant and under-
recognized clinical problem. The overall frequency of 
ocular metastasis in patients dying of cancer is 
approximately 16%, and of lung cancer rises about 40%. 
Careful ophthalmologic examination can make a 
diagnosis. Radiotherapy is the primary management and 
allows the most of the patients to maintain useful vision. 
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